JP2023505217A5 - - Google Patents

Info

Publication number
JP2023505217A5
JP2023505217A5 JP2022533413A JP2022533413A JP2023505217A5 JP 2023505217 A5 JP2023505217 A5 JP 2023505217A5 JP 2022533413 A JP2022533413 A JP 2022533413A JP 2022533413 A JP2022533413 A JP 2022533413A JP 2023505217 A5 JP2023505217 A5 JP 2023505217A5
Authority
JP
Japan
Prior art keywords
cdr
formulation
seq
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505217A (ja
JP7670713B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063452 external-priority patent/WO2021113739A1/en
Publication of JP2023505217A publication Critical patent/JP2023505217A/ja
Publication of JP2023505217A5 publication Critical patent/JP2023505217A5/ja
Priority to JP2025067240A priority Critical patent/JP2025156294A/ja
Application granted granted Critical
Publication of JP7670713B2 publication Critical patent/JP7670713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533413A 2019-12-05 2020-12-04 皮下投与のための抗ｃｄ３８抗体の製剤 Active JP7670713B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067240A JP2025156294A (ja) 2019-12-05 2025-04-16 皮下投与のための抗ｃｄ３８抗体の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944082P 2019-12-05 2019-12-05
US62/944,082 2019-12-05
PCT/US2020/063452 WO2021113739A1 (en) 2019-12-05 2020-12-04 Formulations of anti-cd38 antibodies for subcutaneous administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067240A Division JP2025156294A (ja) 2019-12-05 2025-04-16 皮下投与のための抗ｃｄ３８抗体の製剤

Publications (3)

Publication Number Publication Date
JP2023505217A JP2023505217A (ja) 2023-02-08
JP2023505217A5 true JP2023505217A5 (https=) 2023-12-08
JP7670713B2 JP7670713B2 (ja) 2025-04-30

Family

ID=74130308

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533413A Active JP7670713B2 (ja) 2019-12-05 2020-12-04 皮下投与のための抗ｃｄ３８抗体の製剤
JP2025067240A Pending JP2025156294A (ja) 2019-12-05 2025-04-16 皮下投与のための抗ｃｄ３８抗体の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067240A Pending JP2025156294A (ja) 2019-12-05 2025-04-16 皮下投与のための抗ｃｄ３８抗体の製剤

Country Status (13)

Country Link
US (2) US20210188996A1 (https=)
EP (1) EP4069743A1 (https=)
JP (2) JP7670713B2 (https=)
KR (1) KR20220159947A (https=)
CN (1) CN115698064A (https=)
AU (1) AU2020397170A1 (https=)
BR (1) BR112022010905A2 (https=)
CA (1) CA3160502A1 (https=)
CO (1) CO2022009089A2 (https=)
IL (1) IL293563A (https=)
MX (1) MX2022006882A (https=)
TW (1) TW202133879A (https=)
WO (1) WO2021113739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210030411A (ko) * 2018-07-10 2021-03-17 사노피 Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022010012A (es) * 2020-02-13 2022-09-07 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria.
WO2023212526A1 (en) * 2022-04-26 2023-11-02 Keystone Bio, Inc. Formulation for antigen-binding molecules that bind to porphyromonas gingivalis
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2025240486A1 (en) * 2024-05-14 2025-11-20 Enable Injections, Inc. Device and method for subcutaneous administration of anti-cd38 antibodies
WO2026046348A1 (zh) * 2024-08-30 2026-03-05 杭州九源基因生物医药股份有限公司 抗cd38抗体的稳定药物制剂及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449345A (en) 1989-03-17 1995-09-12 Merit Medical Systems, Inc. Detachable and reusable digital control unit for monitoring balloon catheter data in a syringe inflation system
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5722956A (en) 1995-08-24 1998-03-03 The General Hospital Corporation Multi-dose syringe driver
US6645177B1 (en) 1999-02-09 2003-11-11 Alaris Medical Systems, Inc. Directly engaged syringe driver system
US6428509B1 (en) 1999-07-29 2002-08-06 Alaris Medical Systems, Inc. Syringe plunger driver system and method
US7195610B1 (en) 2001-09-17 2007-03-27 Cardinal Health 303, Inc. Pneumatic syringe driver
US7150724B2 (en) 2002-06-05 2006-12-19 Cardinal Health 303, Inc. Syringe plunger driver system
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
US7867197B2 (en) 2006-03-29 2011-01-11 The General Hospital Corporation Single-dose syringe driver
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
WO2016109822A1 (en) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
CA3004152C (en) * 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
MA45674A (fr) * 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20250117714A (ko) * 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
BR112021021099A2 (pt) * 2019-04-23 2021-12-14 Sanofi Sa Formulações de anticorpos estáveis, de baixa viscosidade, e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2023505217A5 (https=)
JP2023517236A5 (https=)
IL276164B1 (en) Anti-tmprss2 antibodies and antigen-binding fragments
CN104684552B (zh) 组合及其用途
JP2016531915A5 (https=)
CN119679936A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2020509027A5 (https=)
JP2021519295A5 (https=)
AU2021221287B2 (en) Engineered anti-IL-2 antibodies
JP2024540054A5 (https=)
EP3122780A2 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
JP2015500822A5 (https=)
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2022523372A5 (https=)
JP2025501028A5 (https=)
JP2025503339A5 (https=)
JP2025503614A5 (https=)
IL258337B2 (en) Antibodies that bind human cannabinoid receptor 1
JP2018533569A5 (https=)
JP2025015588A (ja) 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
JP2024540226A5 (https=)
JP2023520771A5 (https=)
KR20220103969A (ko) 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
CN119424632A (zh) 治疗结直肠癌的联用药物组合物
JP2021523881A5 (https=)